Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TransMedics (TMDX) EPS (Weighted Average and Diluted) (2020 - 2025)

TransMedics has reported EPS (Weighted Average and Diluted) over the past 6 years, most recently at $2.59 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at $2.59 for Q4 2025, up 1195.0% from a year ago — trailing twelve months through Dec 2025 was $4.87 (up 377.45% YoY), and the annual figure for FY2025 was $4.87, up 382.18%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $2.59 at TransMedics, up from $0.66 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for TMDX hit a ceiling of $2.59 in Q4 2025 and a floor of -$0.78 in Q3 2023.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.06 (2023), compared with a mean of $0.11.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): plummeted 212.0% in 2023 and later soared 1266.67% in 2024.
  • TransMedics' EPS (Weighted Average and Diluted) stood at -$0.46 in 2021, then skyrocketed by 56.52% to -$0.2 in 2022, then soared by 160.0% to $0.12 in 2023, then soared by 66.67% to $0.2 in 2024, then surged by 1195.0% to $2.59 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were $2.59 (Q4 2025), $0.66 (Q3 2025), and $0.92 (Q2 2025) per Business Quant data.